Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells

British Journal of Haematology

Volumn 111, Issue 2, 2000, Pages 580-586

  Cappellini, M D ^a,b   Robbiolo, L ^a   Bottasso, B M ^a   Coppola, R ^a   Fiorelli, G ^a   Mannucci, P M ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

ALL; Apoptosis; CD40; FLIP; TRAIL

Indexed keywords

CD40 ANTIGEN; RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; APOPTOSIS; ARTICLE; CELL KILLING; CELL SURVIVAL; CHILD; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; TUMOR CELL;

ADOLESCENT; ANTIGENS, CD95; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CARRIER PROTEINS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CD40 LIGAND; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JURKAT CELLS; LEUKEMIA, B-CELL, ACUTE; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR DECOY RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034533011     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02404.x     Document Type: Article

References (33)

1. Apoptosis control by death and decoy receptors
2. Safety and antitumor activity of recombinant soluble Apo2 ligand
3. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway
4. Unbalanced expression of Fas and CD40 in mantle cell lymphoma
5. Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells
6. To die or not to die - The quest of the TRAIL receptors
7. The novel receptor TRAIL-R4 induces NF-Kappa-B and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain
8. Cell death: TRAIL and its receptors
9. TRAIL: A molecule with multiple receptors and control mechanisms
10. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
11. Functional analysis of TRAIL receptors using monoclonal antibodies
12. How TRAIL kills cancer cells, but not normal cells
13. Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bc1-2 induction
14. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers
15. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL
16. A novel receptor for Apo2L/TRAIL contains a truncated death domain
17. The receptor for the cytotoxic ligand TRAIL
18. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling
19. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
20. Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity
21. Characterization of two receptors for TRAIL
22. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB
23. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
24. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies
25. Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells
26. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL
27. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
28. Identification and characterization of a new member of the TNF family that induces apoptosis
29. The dynamics of life and death of malignant lymphocytes
30. CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders
31. CD30 ligand in lymphoma patients with CD30+ tumors
32. Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia
33. Functional expression of TRAIL by lymphoid and myeloid tumour cells